Previous Article | Next Article 
Applied and Environmental Microbiology, October 2005, p. 6407-6409, Vol. 71, No. 10
0099-2240/05/$08.00+0 doi:10.1128/AEM.71.10.6407-6409.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
High Prevalence of VanA-Type Vancomycin-Resistant Enterococci in Austrian Poultry
Alexandra Eisner,1*
Gebhard Feierl,1
Gregor Gorkiewicz,1
Franz Dieber,2
Harald H. Kessler,1
Egon Marth,1 and
Josef Köfer2
Institute of Hygiene, Medical University of Graz,1
Department of Veterinary Administration in Styria, A-8010 Graz, Austria2
Received 23 December 2004/
Accepted 10 May 2005

ABSTRACT
Fecal samples from humans and food-producing animals were analyzed
for the presence of vancomycin-resistant enterococci (VRE).
The VRE carriage rate in humans was 6%, and there was a predominance
of VanC-type resistance.
Enterococcus faecium with
vanA-mediated
resistance was frequent in broiler chickens (42%) but rare in
cattle and pig samples.

INTRODUCTION
In 1986, the first human enterococcal isolates with glycopeptide
resistance were detected in France and the United Kingdom (
18,
25). Since then, vancomycin-resistant enterococci (VRE) have
become a serious cause of nosocomial infections worldwide (
12).
Resistance to glycopeptides in enterococci is mediated by the
vanA,
vanB,
vanC,
vanD,
vanE, or
vanG gene cluster, and the
vanA genotype is considered to be of major importance (
3,
4,
9,
21). The
vanA genotype is the predominant type of resistance
reported in Europe; it is characterized by acquired inducible
resistance to both vancomycin and teicoplanin and is transferable
to other significant pathogens, like methicillin-resistant
Staphylococcus aureus, due to its location on conjugative plasmids (
10,
26).
The
vanB gene cluster confers inducible resistance to various
levels of vancomycin, and isolates exhibit susceptibility to
teicoplanin since this antibiotic is not an inducer. VanC-type
glycopeptide resistance is characterized by chromosomally encoded
and constitutively expressed resistance to low levels of vancomycin
but susceptibility to teicoplanin. This resistance has been
described as an intrinsic property of
Enterococcus gallinarum,
Enterococcus casseliflavus, and
Enterococcus flavescens (
4).
The remaining genotypes appear to occur infrequently among clinical
isolates of VRE. In Europe, the use of the growth promoter avoparcin
is thought to have selected for VRE in animal husbandry (
1,
5,
16). Because VRE can be transferred from food animals to
humans, the use of avoparcin was banned in all European countries
in 1997. Consequently, several studies have shown that there
has been a decline in the occurrence of VRE in fecal samples
of food-producing animals, meat products, and healthy volunteers
(
6,
17,
24). In Austrian hospitals, the level of cases of human
VRE infection or colonization remains low, and nosocomial cross
transmission is considered a primary cause of acquisition of
VRE (
22).
The aim of the present study was to investigate the prevalence of VRE in southeast Austrian animal husbandry (cattle, pigs, and broilers) and in healthy volunteers. Moreover, the patterns of resistance of VRE obtained from animal husbandry to relevant clinical antimicrobials were determined.
A total of 619 animal fecal samples were obtained from different slaughterhouses; 208 cattle fecal samples originated from animals from 136 farms, 206 pig fecal samples originated from animals from 150 farms, and 205 broiler fecal samples originated from animals from 58 farms. Additionally, 200 human fecal specimens (127 females and 73 males; age range, 1 to 90 years) derived from nonhospitalized persons were investigated for the presence of VRE. None of the people had received antibiotic therapy during the previous 4 weeks.
One milliliter of a 10-fold-diluted fecal sample in 0.9% NaCl was added to 9 ml of Enterococcosel broth (BD Diagnostic Systems, Sparks, Md.) for enrichment. After incubation at 35°C for 24 h, 100 µl was subcultured onto vancomycin screen agar plates containing 6 mg vancomycin per liter (BD) and onto Colombia blood agar without vancomycin (BD) and incubated at 35°C for 24 h. Three colonies were randomly selected from each screening plate and subcultured on blood agar. All enterococcal isolates were identified on the basis of colony morphology, Gram staining, catalase and pyrrolidonyl arylamidase activities, Lancefield group D antigen, motility, yellow pigment production, and the 20 Strep and Rapid ID32 Strep API tests (bioMérieux, Marcy l'Etoile, France). The antibiotic susceptibility was determined with the VITEK 2 system (bioMérieux) using an AST-P524 test card (19). Additionally, MICs of vancomycin and teicoplanin were determined by the Etest method (AB Biodisk, Solna, Sweden), and the results were interpreted using the criteria recommended by the National Committee for Clinical Laboratory Standards (23). The glycopeptide resistance genotype was determined by PCR as described previously (11, 15).
The genotypes and species of VRE isolated from both animal and human sources are shown in Table 1. VRE were recovered from 45 of 208 (21.6%) cattle specimens, 48 of 206 (23.3%) pig specimens, and 158 of 205 (77.1%) broiler specimens. A total of 269 VRE were isolated from the animal fecal samples. Of these, 47 originated from cattle specimens, 49 originated from pig specimens, and 173 originated from broiler specimens. In total, 107 E. gallinarum strains and 63 E. casseliflavus strains were identified. As shown by PCR, all the E. gallinarum strains harbored the vanC1 gene, and all the E. casseliflavus strains harbored the vanC2 gene. No E. faecalis strains with glycopeptide resistance were detected. Ninety-nine VanA-type isolates were identified; these isolates included 88 Enterococcus faecium strains and 11 Enterococcus durans strains. All of these isolates expressed high-level vancomycin resistance (MICs,
256 mg/liter) and possessed the vanA gene, as confirmed by PCR. Except for one E. faecium isolate from cattle feces, all E. faecium vanA isolates originated from broiler fecal samples. The results of antibiotic susceptibility testing of the VRE isolates from animal sources obtained with the VITEK 2 system are shown in Table 2. High-level gentamicin resistance was seen in only two E. faecium isolates. Resistance to penicillin was found in 76% of the E. faecium isolates. The rates of resistance to ciprofloxacin and erythromycin differed for different Enterococcus species. High percentages of E. faecium (93%) and E. gallinarum (73%) isolates were found to be tetracycline resistant. Of the E. faecium isolates, 11% showed resistance or reduced susceptibility to quinupristin-dalfopristin. All VRE isolates were found to be susceptible to linezolid. Analysis of human stool samples revealed VRE carriage in 12 of 200 samples (6%). Nine E. gallinarum isolates, two E. casseliflavus isolates, and one E. faecium isolate with vanA-mediated resistance were found.
Avoparcin was used as a growth promoter in broiler chicken,
pig, and cattle husbandry in Austria, but it was banned 7 years
ago. Surprisingly, we still found a high prevalence of VanA
isolates in southeast Austrian poultry, whereas the prevalence
in the pig and cattle specimens was low. We report here the
first enterococcal isolates with high-level vancomycin resistance
obtained from Austrian animal husbandry. Our results are in
contrast to a recent study which reported the absence of VRE
in food-producing animals (cows, pigs, and hens) in western
Austria (
22). The results of Mellmann et al., however, are not
directly comparable to our results because the enrichment step
was not included in their study. Incubation of specimens in
enrichment broth was shown to be superior for isolation of VRE
compared to direct isolation on vancomycin-supplemented plates
(
8). The reason for the high prevalence in southeast Austrian
poultry remains unclear. Continuing high prevalence of
E. faecium with VanA-type resistance despite discontinuation of the use
of avoparcin has been described for Norwegian and Danish poultry
farms (
7,
13).
E. faecalis with VanA-type resistance has also
been shown to persist in the absence of avoparcin usage in New
Zealand (
20). The data indicate that the continuing occurrence
of VRE in broiler flocks may be explained by persistence of
VRE in the broiler house environment (
14). In Danish pig herds,
coselection by use of macrolides for therapy and growth promotion
was described to be a mechanism for the persistence of glycopeptide
resistance (
2). In our study, only 28% of the vancomycin-resistant
E. faecium isolates showed resistance to erythromycin, indicating
that the linkage of resistance to macrolides and glycopeptides
cannot be the only causative factor for the ongoing persistence.
In Austria, tetracycline is a major antimicrobial used in broiler
production, and the levels of resistance of VRE to this compound
reflect this. Further investigations to clarify the possible
coselection of VRE by tetracycline use are necessary. Little
is known about the coselective capability of ionophore feed
additives or metallic ions which might also select for VRE.
Other potential mechanisms for the persistence include direct
selective pressure by residues of avoparcin in the farm environment
and transmission of resistant bacteria by eggs (
7,
14). The
high rate of resistance to penicillin in VanA-type
E. faecium isolates from poultry investigated in the current study should
be noted. Moreover, 11% of the vancomycin-resistant
E. faecium strains were not susceptible to quinupristin-dalfopristin, suggesting
that the use of the antimicrobial feed additive virginiamycin,
although banned, has created a reservoir of streptogramin-resistant
E. faecium in our study population. Limited data are available
on the prevalence of human VRE colonization in Austria. A study
in western Austria did not reveal any VRE carrier among 433
healthy volunteers (
22). Similarly, one VanA-type VRE carrier
was detected in our study, indicating that there is a minor
VRE reservoir in the southeast Austrian community.
Although the number of cases of human VRE infections in Austrian hospitals is low, the agricultural VRE reservoir that still exists may threaten the community and human medicine because of the possible conjugative vanA gene transfer from enterococci to methicillin-resistant S. aureus, creating a dangerous pathogen that is difficult to treat (10, 22, 26). Surveillance of the VRE reservoir in animal husbandry and further investigations to clarify the mechanisms for persistence of VanA resistance are urgently required.

ACKNOWLEDGMENTS
We thank Neil Woodford for a critical review of the manuscript.

FOOTNOTES
* Corresponding author. Mailing address: Institute of Hygiene, Medical University of Graz, Universitätsplatz 4, A-8010 Graz, Austria. Phone: 43(316)380-4383. Fax: 43(316)380-9648. E-mail:
alexandra.eisner{at}meduni-graz.at.


REFERENCES
1 - Aarestrup, F. M. 1995. Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb. Drug Resist. 1:255-257.[Medline]
2 - Aarestrup, F. M. 2000. Characterization of glycopeptide-resistant Enterococcus faecium (GRE) from broilers and pigs in Denmark: genetic evidence that persistence of GRE in pig herds is associated with coselection by resistance to macrolides. J. Clin. Microbiol. 38:2774-2777.[Abstract/Free Full Text]
3 - Abadia Patino, L., P. Courvalin, and B. Perichon. 2002. vanE gene cluster of vancomycin-resistant Enterococcus faecalis BM4405. J. Bacteriol. 184:6457-6464.[Free Full Text]
4 - Arthur, M., P. Reynolds, and P. Courvalin. 1996. Glycopeptide resistance in enterococci. Trends Microbiol. 4:401-407.[CrossRef][Medline]
5 - Bager, F., M. Madsen, J. Christensen, and F. M. Aarestrup. 1997. Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Prev. Vet. Med. 31:95-112.[CrossRef][Medline]
6 - Bager, F., F. M. Aarestrup, M. Madsen, and H. C. Wegener. 1999. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb. Drug Resist. 5:53-56.[Medline]
7 - Borgen, K., M. Sorum, Y. Wasteson, and H. Kruse. 2001. VanA-type vancomycin-resistant enterococci (VRE) remain prevalent in poultry carcasses 3 years after avoparcin was banned. Int. J. Food Microbiol. 64:89-94.[CrossRef][Medline]
8 - Butaye, P., L. A. Devriese, and F. Haesebrouck. 1999. Comparison of direct and enrichment methods for the selective isolation of vancomycin-resistant enterococci from feces of pigs and poultry. Microb. Drug Resist. 5:131-134.[Medline]
9 - Casadewall, B., and P. Courvalin. 1999. Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339. J. Bacteriol. 181:3644-3648.[Abstract/Free Full Text]
10 - Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.[Free Full Text]
11 - Elsayed, S., N. Hamilton, D. Boyd, and M. Mulvey. 2001. Improved primer design for multiplex PCR analysis of vancomycin-resistant Enterococcus spp. J. Clin. Microbiol. 39:2367-2368.[Free Full Text]
12 - Hayden, M. K. 2000. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin. Infect. Dis. 31:1058-1065.[CrossRef][Medline]
13 - Heuer, O. E., K. Pedersen, J. S. Andersen, and M. Madsen. 2002. Vancomycin-resistant enterococci (VRE) in broiler flocks 5 years after the avoparcin ban. Microb. Drug Resist. 8:133-138.[CrossRef][Medline]
14 - Heuer, O. E., K. Pedersen, L. B. Jensen, M. Madsen, and J. E. Olsen. 2002. Persistence of vancomycin-resistant enterococci (VRE) in broiler houses after the avoparcin ban. Microb. Drug Resist. 8:355-361.[CrossRef][Medline]
15 - Kariyama, R., R. Mitsuhata, J. W. Chow, D. B. Clewell, and H. Kumon. 2000. Simple and reliable multiplex PCR assay for surveillance isolates of vancomycin-resistant enterococci. J. Clin. Microbiol. 38:3092-3095.[Abstract/Free Full Text]
16 - Klare, I., H. Heier, H. Claus, R. Reissbrodt, and W. Witte. 1995. vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol. Lett. 125:165-171.[CrossRef][Medline]
17 - Klare, I., D. Badstubner, C. Konstabel, G. Bohme, H. Claus, and W. Witte. 1999. Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. Microb. Drug Resist. 5:45-52.[Medline]
18 - Leclercq, R., E. Derlot, J. Duval, and P. Courvalin. 1988. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157-160.[Medline]
19 - Ligozzi, M., C. Bernini, M. G. Bonora, M. De Fatima, J. Zuliani, and R. Fontana. 2002. Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. J. Clin. Microbiol. 40:1681-1686.[Abstract/Free Full Text]
20 - Manson, J. M., J. M. Smith, and G. M. Cook. 2004. Persistence of vancomycin-resistant enterococci in New Zealand broilers after the discontinuation of avoparcin use. Appl. Environ. Microbiol. 70:5764-5768.[Abstract/Free Full Text]
21 - McKessar, S. J., A. M. Berry, J. M. Bell, J. D. Turnidge, and J. C. Paton. 2000. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob. Agents Chemother. 44:3224-3228.[Abstract/Free Full Text]
22 - Mellmann, A., D. Orth, M. P. Dierich, F. Allerberger, I. Klare, and W. Witte. 2000. Nosocomial cross transmission as a primary cause of vancomycin-resistant enterococci in Austria. J. Hosp. Infect. 44:281-287.[CrossRef][Medline]
23 - National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing. Supplement M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24 - Pantosti, A., M. Del Grosso, S. Tagliabue, A. Macri, and A. Caprioli. 1999. Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban. Lancet 354:741-742.[CrossRef][Medline]
25 - Uttley, A. H., C. H. Collins, J. Naidoo, and R. C. George. 1988. Vancomycin-resistant enterococci. Lancet i:57-58.
26 - Whitener, C. J., S. Y. Park, F. A. Browne, L. J. Parent, K. Julian, B. Bozdogan, P. C. Appelbaum, J. Chaitram, L. M. Weigel, J. Jernigan, L. K. McDougal, F. C. Tenover, and S. K. Fridkin. 2004. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. 38:1049-1055.[CrossRef][Medline]
Applied and Environmental Microbiology, October 2005, p. 6407-6409, Vol. 71, No. 10
0099-2240/05/$08.00+0 doi:10.1128/AEM.71.10.6407-6409.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Marrow, J., Whittington, J. K., Mitchell, M., Hoyer, L. L., Maddox, C.
(2009). PREVALENCE AND ANTIBIOTIC-RESISTANCE CHARACTERISTICS OF ENTEROCOCCUS SPP. ISOLATED FROM FREE-LIVING AND CAPTIVE RAPTORS IN CENTRAL ILLINOIS. J Wildl Dis
45: 302-313
[Abstract]
[Full Text]